Orthofix Medical (OFIX) Stock Forecast, Price & News

Orthofix Medical's stock was trading at $20.53 at the beginning of 2023. Since then, OFIX stock has decreased by 3.9% and is now trading at $19.72.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our OFIX earnings forecast.

Orthofix Medical Inc. (NASDAQ:OFIX) issued its quarterly earnings results on Monday, March, 6th. The medical device company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.56. The medical device company earned $122.23 million during the quarter, compared to analysts' expectations of $121.90 million. Orthofix Medical had a negative trailing twelve-month return on equity of 2.14% and a negative net margin of 14.40%. During the same quarter in the previous year, the company earned $0.27 earnings per share.

ETFs with the largest weight of Orthofix Medical (NASDAQ:OFIX) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Nasdaq Future Gen 200 ETF (QQQS), Syntax Stratified SmallCap ETF (SSLY), Invesco S&P SmallCap 600 Pure Value ETF (RZV), IQ Chaikin U.S. Small Cap ETF (CSML), iShares Micro-Cap ETF (IWC) and Principal Healthcare Innovators ETF (BTEC).

Orthofix Medical updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $750.00 million-$756.00 million, compared to the consensus revenue estimate of $748.69 million.

32 employees have rated Orthofix Medical Chief Executive Officer Brad Mason on Glassdoor.com. Brad Mason has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Edwards Lifesciences (EW), Gilead Sciences (GILD), Biogen (BIIB), Pfizer (PFE), Exxon Mobil (XOM), Advanced Micro Devices (AMD), bluebird bio (BLUE) and Esperion Therapeutics (ESPR).

Orthofix Medical trades on the NASDAQ under the ticker symbol "OFIX."

Orthofix Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.48%), First Light Asset Management LLC (7.27%), Segall Bryant & Hamill LLC (5.72%), Rubric Capital Management LP (5.61%), Armistice Capital LLC (5.04%) and State Street Corp (4.30%). Insiders that own company stock include Catherine M Burzik, Jon Carl Serbousek, Kevin J Kenny, Kimberley A Elting, Michael E Paolucci, Rice Doug and Shweta Maniar.
View institutional ownership trends.

Shares of OFIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OFIX stock can currently be purchased for approximately $19.72.

Orthofix Medical (NASDAQ:OFIX) has a market capitalization of $720.57 million and generates $460.71 million in revenue each year. The medical device company earns $-19,750,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

The company employs 1,092 workers across the globe.

Orthofix Medical's mailing address is 3451 Plano Parkway, Lewisville TX, 75056. The official website for the company is www.orthofix.com. The medical device company can be reached via phone at (214) 937-2000, via email at markquick@orthofix.com, or via fax at 599 9 461 6978.